scholarly journals Circulating Nesfatin-1 Levels and Type 2 Diabetes: A Systematic Review and Meta-Analysis

2017 ◽  
Vol 2017 ◽  
pp. 1-8 ◽  
Author(s):  
Ting Zhai ◽  
Shi-Zhen Li ◽  
Xin-Tong Fan ◽  
Zhao Tian ◽  
Xiao-Qing Lu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Meta Analysis ◽  
Control Group ◽  
Newly Diagnosed ◽  
Antidiabetic Treatment ◽  
The Relationship ◽  
Diabetes Patients

The role of nesfatin-1 in glucose homeostasis has been investigated previously. However, although numerous studies have examined the relationships between circulating nesfatin-1 levels and type 2 diabetes, the conclusions are contradictory. We aimed to probe the relationship between circulating nesfatin-1 levels and type 2 diabetes by meta-analysis. Seven studies including 328 type 2 diabetes patients and 294 control subjects were included. Although there was no obvious difference in circulating nesfatin-1 levels between patients with type 2 diabetes and the control group (MD = −0.04; 95% CI = −0.32 to −0.23), subgroup analysis showed higher nesfatin-1 levels in newly diagnosed type 2 diabetes patients (MD = 0.59; 95% CI = 0.45 to 0.74) and significantly lower nesfatin-1 levels in type 2 diabetes patients receiving antidiabetic treatment (MD = −0.26; 95% CI = −0.33 to −0.20). In conclusion, the analysis supports a relationship between circulating nesfatin-1 levels and type 2 diabetes, where newly diagnosed type 2 diabetes was associated with an elevated Nesfatin-1 level, and type 2 diabetes patients receiving antidiabetic treatment showed lower circulating nesfatin-1 levels.

scholarly journals Prevalence of Type 2 Diabetes in South Africa: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 18 (11) ◽  
pp. 5868
Author(s):  
Carmen Pheiffer ◽  
Victoria Pillay-van Wyk ◽  
Eunice Turawa ◽  
Naomi Levitt ◽  
Andre P. Kengne ◽  
...  
Keyword(s):  
South Africa ◽  
Systematic Review ◽  
Type 2 Diabetes ◽  
Health Planning ◽  
Meta Analysis ◽  
Population Group ◽  
Significant Heterogeneity ◽  
Newly Diagnosed ◽  
Prevalence Data

Synthesis of existing prevalence data using rigorous systematic review methods is considered an effective strategy to generate representative and robust prevalence figures to inform health planning and policy. The purpose of this systematic review was to identify, collate, and synthesise all studies reporting the prevalence of total and newly diagnosed type 2 diabetes (T2DM), impaired glucose tolerance (IGT), and impaired fasting glucose (IFG) in South Africa. Four databases, PubMed, Scopus, Web of Science, and African Index Medicus were searched for articles published between January 1997 and June 2020. A total of 1886 articles were identified, of which 11 were included in the meta-analysis. The pooled prevalence in individuals 25 years and older was 15.25% (11.07–19.95%) for T2DM, 9.59% (5.82–14.17%) for IGT, 3.55% (0.38–9.61%) for IFG, and 8.29% (4.97–12.34%) for newly diagnosed T2DM. Although our pooled estimate may be imprecise due to significant heterogeneity across studies with regard to population group, age, gender, setting, diagnostic test, and study design, we provide evidence that the burden of glucose intolerance in South Africa is high. These factors contribute to the paucity of representative T2DM prevalence data. There is a need for well-designed epidemiological studies that use best-practice and standardised methods to assess prevalence.

scholarly journals Impact of Prediabetes and Type-2 Diabetes on Outcomes in Patients with COVID-19

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Jasbir Makker ◽  
Haozhe Sun ◽  
Harish Patel ◽  
Nikhitha Mantri ◽  
Maleeha Zahid ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Mechanical Ventilation ◽  
Older Patients ◽  
Control Group ◽  
Newly Diagnosed ◽  
Conflicting Evidence ◽  
Diabetes Status ◽  
Binomial Regression ◽  
Diabetes Patients

Introduction. The true impact of prediabetes and type-2 diabetes in patients with COVID-19 remains unknown, with studies thus far providing conflicting evidence. Methods. This is a single-center retrospective observational study involving 843 hospitalized patients with SARS-CoV-2 infection. Primary outcomes, mortality, and mechanical ventilation use were compared among the three groups: control, prediabetes, and type-2 diabetes. Binomial regression analysis was used to determine predictors of mortality and mechanical ventilation requirement. Results. Age was a significant predictor of mortality. On stratifying our patients based on their age, older patients aged 55 years and above had no difference in mortality or mechanical ventilation requirement among the three groups of control, prediabetes, and type-2 diabetes. However, among the younger population aged less than 55 years, patients with type-2 diabetes had significantly higher mortality as compared with patients in control and prediabetes groups (27% vs 12.5% vs 9%, p   0.025 ). Additionally, newly diagnosed type-2 diabetes patients demonstrated lower mortality rate in comparison to previously known type-2 diabetes patients (18% vs 40%, p   0.005 ). Outcomes in the prediabetes group were similar to that in the control group. Admission hyperglycemia was associated with higher mortality regardless of diabetes status. Conclusion. In older patients aged 55 years and above, status of type-2 diabetes does not influence their mortality. However, in younger patients aged less than 55 years, the presence of type-2 diabetes is an important driver of mortality. Newly diagnosed type-2 diabetes, in comparison with previously diagnosed type-2 diabetes, may have better survival. Presence of prediabetes did not affect outcomes in patients with COVID-19 infection.

scholarly journals Related factors of quality of life of type 2 diabetes patients: a systematic review and meta-analysis

2018 ◽  
Vol 16 (1) ◽  
Author(s):  
Xiyue Jing ◽  
Jiageng Chen ◽  
Yanan Dong ◽  
Duolan Han ◽  
Haozuo Zhao ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Systematic Review ◽  
Type 2 Diabetes ◽  
Meta Analysis ◽  
Related Factors ◽  
Diabetes Patients

scholarly journals The Role of Aerobic Training Variables Progression on Glycemic Control of Patients with Type 2 Diabetes: a Systematic Review with Meta-analysis

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Rodrigo Sudatti Delevatti ◽  
Cláudia Gomes Bracht ◽  
Salime Donida Chedid Lisboa ◽  
Rochelle Rocha Costa ◽  
Elisa Corrêa Marson ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Aerobic Training ◽  
Meta Analysis

scholarly journals Cost Utility of Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Metformin Monotherapy Failed Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis

2019 ◽  
Vol 22 (12) ◽  
pp. 1458-1469 ◽  
Author(s):  
Bhavani Shankara Bagepally ◽  
Yogesh Krishnarao Gurav ◽  
Thunyarat Anothaisintawee ◽  
Sitaporn Youngkong ◽  
Usa Chaikledkaew ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Meta Analysis ◽  
Cost Utility ◽  
Sodium Glucose Cotransporter ◽  
Metformin Monotherapy ◽  
Diabetes Patients

Serum hepcidin, the hepcidin/ferritin ratio and the risk of type 2 diabetes: a systematic review and meta-analysis

2020 ◽  
Vol 27 ◽  
Author(s):  
Nahid Karamzad ◽  
Aziz Eftekhari ◽  
Ahad Ashrafi-Asgarabad ◽  
Mark J.M. Sullman ◽  
Amirhossein Sahebkar ◽  
...  
Keyword(s):  
Systematic Review ◽  
Type 2 Diabetes ◽  
Confidence Interval ◽  
Meta Analysis ◽  
Study Groups ◽  
Risk Marker ◽  
Relationship Type ◽  
Serum Hepcidin ◽  
The Relationship

Objectives: To perform a meta-analysis on the relationship type 2 diabetes has with serum hepcidin and the hepcidin/ferritin ratio. Methods: The following databases were searched using all relevant keywords: Web of Science, Medline, Scopus, Embase and Google Scholar. All studies that examined the relationship type 2 diabetes has with serum hepcidin or the hepcidin/ferritin ratio were included in this meta-analysis and systematic review, provided they were published in English between 2011 and 2018. A random-effects model was used to pool the standardized mean difference (SMD). Results: The SMD of serum hepcidin among patients with type 2 diabetes and healthy controls were compared across eight studies (n cases=878; n controls=2306). The pooled SMD of serum hepcidin did not differ significantly between study groups (SMD: 0.04; 95% confidence interval (CI): -0.29 to 0.35). In contrast, the serum hepcidin/ferritin ratio was examined across five studies (n cases=229; n controls=1426) and was found to be negatively associated with the risk of type 2 diabetes (SMD: -0.52; 95% confidence interval (CI): -0.85 to -0.19). There was no publication bias found for the associations serum hepcidin (Egger´s test: P =0.97) or the hepcidin/ferritin ratio (Egger´s test: P =0.75) had with type 2 diabetes. Conclusions: Although hepcidin has been proposed as a risk marker for type 2 diabetes, our meta-analysis found that the hepcidin/ferritin ratio was superior to hepcidin alone as a risk marker.

Sign in / Sign up

Export Citation Format

Share Document